These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 16047351)
1. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Alaminos M; Gerald WL; Cheung NK Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351 [TBL] [Abstract][Full Text] [Related]
2. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915 [TBL] [Abstract][Full Text] [Related]
3. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167 [TBL] [Abstract][Full Text] [Related]
4. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines. Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333 [TBL] [Abstract][Full Text] [Related]
5. MYCN gene amplification in patients with neuroblastic tumors. Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001 [TBL] [Abstract][Full Text] [Related]
6. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma. Gebauer S; Yu AL; Omura-Minamisawa M; Batova A; Diccianni MB Genes Chromosomes Cancer; 2004 Dec; 41(4):297-308. PubMed ID: 15390183 [TBL] [Abstract][Full Text] [Related]
7. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR. Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822 [TBL] [Abstract][Full Text] [Related]
8. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326 [TBL] [Abstract][Full Text] [Related]
9. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma. Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434 [TBL] [Abstract][Full Text] [Related]
10. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629 [TBL] [Abstract][Full Text] [Related]
11. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology. Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma. Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373 [TBL] [Abstract][Full Text] [Related]
13. [Study on MYCN gene amplification and CD44 expression in neuroblastoma]. Hu HL; He LJ Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318 [TBL] [Abstract][Full Text] [Related]
14. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472 [TBL] [Abstract][Full Text] [Related]
16. The MYCN enigma: significance of MYCN expression in neuroblastoma. Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605 [TBL] [Abstract][Full Text] [Related]
17. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Fulda S; Poremba C; Berwanger B; Häcker S; Eilers M; Christiansen H; Hero B; Debatin KM Cancer Res; 2006 Oct; 66(20):10016-23. PubMed ID: 17047064 [TBL] [Abstract][Full Text] [Related]
18. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091 [TBL] [Abstract][Full Text] [Related]
20. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections. Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]